SCHEMBL23218735

SCHEMBL23218735

Cc1cc2c(o1)c(Br)cc1c(C(=O)O)c(C)oc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
GPR35 Q9HC97 1/20 0.39
MEN1 O00255 7/20 0.39
KMT2A Q03164 7/20 0.39
KEAP1 Q14145 2/20 0.39
NFE2L2 Q16236 2/20 0.39
GAA P10253 2/20 0.38
MAPT P10636 4/20 0.37
CASP6 P55212 2/20 0.37
ACLY P53396 1/20 0.37
SLC26A4 O43511 1/20 0.36
BLM P54132 1/20 0.36
ATM Q13315 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 2/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591463 1.00 POLB (0.40) POLBGPR35MEN1KMT2AKEAP1
SCHEMBL29592686 0.82 MAPT (0.56) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL23219141 0.82 MAPT (0.56) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL29591158 0.79 MEN1 (0.40) POLBMEN1KMT2AKEAP1NFE2L2
SCHEMBL23219102 0.79 MEN1 (0.40) POLBMEN1KMT2AKEAP1NFE2L2
SCHEMBL23219246 0.75 GPR35 (0.44) POLBGPR35MEN1KMT2AMAPT
SCHEMBL29592342 0.75 GPR35 (0.44) POLBGPR35MEN1KMT2AMAPT
SCHEMBL23218992 0.74 NQO1 (0.31) ALDH1A1
SCHEMBL29591413 0.74 NQO1 (0.31) ALDH1A1
SCHEMBL23219033 0.72 ALDH1A1 (0.31) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB POLB 3530/4885GPR35 3426/4885MEN1 1819/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB POLB 2655/4885GPR35 3833/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.